NovaTrace Analytical: impartiality threats created by a group acquisition and a director's shareholding
NovaTrace Analytical is an ISO/IEC 17025:2017 accredited laboratory testing soils, groundwater and leachates for a national environmental regulator and for private developers. Its parent group has just acquired GreenPath, an environmental consultancy that designs remediation plans and now frequently names NovaTrace as the approved testing laboratory in its tender documents. Separately, NovaTrace's commercial director holds a 15% shareholding in a waste-disposal company whose landfill the laboratory has tested monthly for six years. The quality manager treats both situations as commercial matters: every member of staff signs the impartiality statement annually, no analyst has reported pressure, and the impartiality risk register was last reviewed 14 months ago. Two analysts who previously worked for GreenPath now handle samples from GreenPath-designed projects, and one of them sits on the committee that approves GreenPath's remediation designs. The accreditation body is preparing a routine surveillance assessment.
1. Are both situations within the scope of clause 4.1, and on what reasoning? Distinguish what the standard requires of the laboratory as an organisation from what it requires of individual analysts.
Read the worked answer
Clause 4.1 is drafted at the level of the laboratory, not the individual. 4.1.1 requires laboratory activities to be undertaken impartially and requires top management commitment; 4.1.2 makes the laboratory responsible for the impartiality of its activities and forbids allowing commercial, financial or other pressures to compromise impartiality; 4.1.3 requires risks to impartiality to be identified on an ongoing basis, expressly including risks arising from the laboratory's activities, its relationships, or the relationships of its personnel; 4.1.4 requires the laboratory to demonstrate how an identified risk is eliminated or minimised.
The words activities, relationships and personnel are what make both facts relevant. A group relationship with a consultancy that both designs remediation plans and specifies the laboratory in tenders creates a self-referral loop: the same economic interest influences what is designed and who tests it. A 15% shareholding held by a director creates a financial self-interest in a person with influence over pricing, capacity and turnaround priorities for that customer. Neither is cured by a signed declaration.
The analysts' prior employment is a different and weaker point. Prior employment by itself is not a threat once the employment has ended; the threat arises from the specific role - approving GreenPath's designs while also testing the samples those designs generate. That is a self-review threat and is the clearest single breach candidate.
An assessor therefore asks whether the laboratory identified these risks, analysed them and acted proportionately, not whether staff feel pressured.
2. The quality manager argues that 4.1 is satisfied because the impartiality statement is signed annually and no analyst has reported pressure. Evaluate that position and list the evidence an assessor would seek. Would you raise a nonconformity, and against which requirement?
Read the worked answer
The argument confuses a declaration with a control. A signed statement is a commitment device; it says nothing about whether relationships were identified, analysed and mitigated. The absence of reported pressure is even weaker: staff under commercial pressure frequently do not report it, and here an analyst sits on a customer-facing design committee, which suggests nobody recognised the risk in the first place - nobody can report a risk that the system does not name.
Evidence to request: the impartiality risk register with its review dates and analysis, and the laboratory's own procedure setting its review interval (14 months is only a finding if the laboratory's procedure sets a shorter period); records of top management review of impartiality, including management review inputs; the tender and contract file showing how GreenPath's specification of NovaTrace is handled and whether the laboratory reviews requests for conflicts at 7.1; personnel files showing declarations, recusals and any conditions attached to the analyst's committee role; and the sample acceptance records for the landfill customer.
I would raise a nonconformity against 4.1, most precisely 4.1.3 with 4.1.4, because the laboratory has not shown that it identifies and addresses risks arising from its relationships and from the relationships of its personnel. The stale risk register is supporting evidence, not the finding itself. If the laboratory had identified the risks but the recorded action was clearly inadequate, the finding sits at 4.1.4 instead. The distinction matters for the corrective action the laboratory must produce.
3. What must NovaTrace do about the director's shareholding before the surveillance assessment, and how would your conclusion change if the holding were 0.5% rather than 15%?
Read the worked answer
A material financial interest held by someone who can influence which samples are accepted, when they are tested and what is charged is a self-interest threat. 4.1.2 prohibits allowing that pressure to compromise impartiality, and 4.1.4 requires the laboratory to demonstrate how it eliminates or minimises the risk. A declaration alone does not demonstrate anything.
Options, strongest first: divest the holding; remove the director from all decisions concerning that customer (pricing, acceptance, priority, staffing, result release), documented through delegations of authority, LIMS access controls and a written instruction, with records proving the recusal operates in practice; add independent technical review of that facility's data by a manager outside the director's reporting line; transfer the customer relationship to a manager with no interest. Disclosure plus review is acceptable only if the reviewer genuinely can change the outcome; if every result still passes the director's desk, the mitigation is theatre.
How the assessor tests it: can the director override a decision? Can they see results in the system? Is the affected customer named on a controlled list? Are there records of the recusal actually being applied?
The 0.5% variant: size is relevant but the criterion is not a percentage - it is the potential to influence judgement. A passive, immaterial holding in a large listed company, with no role in decisions affecting that customer, can be acceptable on disclosure. A holding in a single-plant company whose only site the laboratory tests is a different risk whatever the number. The laboratory should document the rationale, and the assessor should test the rationale rather than the figure.